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Recent studies (1–4) documented the highly 
destructive nature of acute HIV infection: a 
massive loss of memory CD4 T cells through-
out the body, particularly at mucosal surfaces, 
precedes emerging antiviral responses. This 
assault on preexisting memory CD4 T cells 
was hypothesized to disable the ability of the 
immune system to generate secondary im-
mune responses, setting the stage for immuno-
defi  ciency. Therefore, an important goal of 
an HIV vaccine is to prevent or contain the
early destruction of CD4 T cells, thereby pre-
serving and maintaining the integrity of the 
  immune system.
Numerous vaccine regimens have been 
tested in animal models that suggest partial 
  protection based on measures of plasma viral 
loads (VLs) and total blood CD4 T cell counts 
(5–10). However, these surrogates overlook the 
underlying destruction of the memory CD4 
T cells that occurs in all tissues. Thus, in contrast 
to the commonly described partial and transient 
loss of total CD4 T cells during acute infection, 
a substantial fraction (50–80%) of memory 
T cells across both mucosal and peripheral tis-
sues are infected and destroyed within the fi  rst 
2 wk of infection (1). This destruction may be 
a central mechanism accounting for subsequent 
immune failure.
As memory CD4 T cells are critical for 
maintaining immune competence while serv-
ing as the primary target of HIV infection, the 
evaluation of a potential vaccine’s effi   cacy must 
include its ability to prevent infection and 
  destruction of these cells. In addition, newly 
emerging HIV-specifi  c CD4 T cells may also 
serve as preferential targets for infection (11, 12). 
Destruction of these cells could impair the 
  generation and maintenance of antiviral CD8 
T cell responses. Given the tissue-specifi  c dif-
ferences in composition of CD4 T cells, it is 
important that such evaluation be made across 
multiple tissues, such as the mucosa and LNs. 
Notably, the high and variable contribution of 
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naive CD4 T cells, which are uninvolved in acute infection, 
signifi  cantly skews the interpretation of HIV (and simian im-
munodefi  ciency virus [SIV])-associated changes during acute 
disease by masking the extent of the ongoing destruction.
We demonstrated previously that acute SIV infection is 
accompanied by a massive infection and destruction of mem-
ory CD4 T cells (1). Here, we sought to determine whether 
prior vaccination could preserve memory CD4 T cells and 
whether such preservation is associated with better long-term 
outcome and survival. We evaluated the eff  ects of a DNA-
prime recombinant adenovirus (rAd) boost vaccine regimen 
on cell-associated VL and memory CD4 T cell dynamics in 
peripheral and mucosal tissues. We show that prior vaccina-
tion induced plasma-neutralizing antibody as well as T cell 
immune responses in various tissues that signifi  cantly reduced 
the level of infection and destruction of the memory CD4 
T cells after intravenous challenge. Importantly, although 
vaccine-induced SIV-specifi  c CD4 T cells were preferen-
tially infected, this was not associated with loss of protection. 
In fact, the vaccine-induced protection of memory CD4 
T cells was associated with a better long-term outcome and 
survival in infected animals.
RESULTS
Vaccination tempers viral dynamics
12 rhesus macaques were vaccinated with a regimen consisting 
of a DNA prime followed by rAd boost. Six animals received 
a sham vaccine, and the other six received plasmids and rAd 
separately encoding SIVMac239 envelope and an SIVMac239 
gag-pol fusion protein (13). Three shots of DNA were given 
at 1-mo intervals, and one shot of rAd was given 3 mo after 
the last DNA immunization. Animals were challenged with 
SIV Mac251 2 mo after the rAd immunization. Animals were 
killed at diff  erent time points after challenge. Biopsies and 
  necropsies provided serial tissue specimens (Table I).
As published previously (5–10), vaccination signifi  cantly 
suppressed peak plasma VLs in most animals by  1 log, with 
an apparently faster resolution compared with sham (Fig. 1 a). 
Because plasma VL refl  ects actively replicating virus, these 
results suggest that vaccination-induced immune responses 
reduced the number of cells that were infected and/or more 
rapidly destroyed the infected CD4 T cells. Notably, the pro-
tection was variable, with one animal (no. 4934; closed green 
circles) exhibiting peak plasma VLs at levels comparable to 
unvaccinated animals. Nonetheless, some protection was evi-
dent in this animal, as it appeared to resolve plasma VLs faster 
and to a lower level than the sham-vaccinated animals.
In sham-vaccinated animals, as shown previously (1), the 
cell-associated VL reveals a massive infection (and subsequent 
destruction) of memory CD4 T cells in blood and jejunum 
(Fig. 1 b). We showed previously (1) that longitudinal analysis 
of cell-associated VL dynamics (SIV-gag copies/memory CD4 
T cell) is a predictor of the number of cells infected and de-
stroyed during acute infection. Notably, studies in humans 
demonstrated that levels of HIV DNA in PBMCs soon after 
infection were predictive of disease progression independently 
of HIV-1 RNA levels and CD4 T cell counts (14). In the 
  animals, vaccination signifi  cantly reduced the peak infection of 
memory CD4 T cells by  75% (Fig. 1 b) and signifi  cantly 
tempered the destruction occurring during acute infection.
Vaccination preserves memory CD4 T cells 
in multiple tissues
The tempered rate of infection and loss of CD4 memory T cells 
in vaccinated animals suggested that the dynamics of memory 
T cell loss measured phenotypically would be dramatically 
diff  erent compared with sham-vaccinated animals. Naive and 
memory T cells were identifi  ed on the basis of expression of 
CD45RA and CD95 as shown in Fig. S1 (available at http://
www.jem.org/cgi/content/full/jem.20060657/DC1); naive 
T cells are CD95–CD45RA+ and memory T cells are all other 
cells. Fig. 2 a illustrates that the ratio of naive to memory cells 
in all three lymphoid tissues (there are essentially no naive 
cells in the jejunum) increases in sham-vaccinated animals due 
to the destruction of memory cells. In contrast, the minor 
decrease in the naive/memory ratio observed in vaccinated 
animals is consistent with the preservation of CD4 memory 
T cells (after the very early expansion of CD4 memory cells 
consistently observed after challenge [1]).
By normalizing the representation of CD4 memory 
T cells within each animal to its prechallenge time point, the 
preservation aff  orded by vaccination is seen in all tissues (Fig. 
2 b). In comparison to sham-treated animals, vaccinated ani-
mals showed a signifi  cantly lower loss of CD4 memory cells. 
The preservation was greatest in the peripheral lymphoid 
  tissues. In jejunal (mucosa) tissues,  25% of memory CD4 
T cells were preserved. Nonetheless, preservation of this 
  fraction of memory CD4 T cells in the mucosa could have 
Table I.  Tissue sampling schedule
Sham animal Vaccine animal Blood Jejunum Inguinal LN Mesenteric LN
4939  4750  P, 0, 7 P, 0, 7 P, 0, 7 P, 7
4975  4736  P, 0, 7, 10 P, 7, 10 P, 7, 10 P, 10
4875  4942  P, 0, 7, 10, 14 P, 10, 14 P, 10, 14 P, 14
4931   4974  P, 0, 7, 10, 14, 17 P, 14, 17 P, 14, 17 P, 17
5510   4844  P, 0, 7–14, 17, 21 P, 17, 21 P, 17, 21 P, 21
4755  4934  P, 0, 7–14, 17, 21, 28 P, 21, 28 P, 21, 28 P, 28
Listed are the days after infection (P = 1 mo before infection) at which samples were collected from each animal in the group. For four animals, 1 mL blood was collected 
daily between days 7 and 14 after infection. All other collections were 5 mL blood. The last collection date was a necropsy. All animals sustained only a single survival surgery.JEM VOL. 203, June 12, 2006  1535
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a dramatic benefi  t immunologically compared with the well-
documented complete destruction of jejunal CD4 memory 
cells in unvaccinated animals (1, 2, 4, 15). Collectively, these 
fi  ndings demonstrate that systemic vaccination with DNA/
rAd can signifi  cantly protect against the complete destruction 
of CD4 memory cells during the acute phase.
Vaccination induced both humoral and cellular 
immune responses
Numerous studies have shown that neutralizing antibodies 
and/or T cell responses were critical for controlling viral in-
fection (16–26). We quantifi  ed both the neutralizing anti-
body and eff  ector T cell responses induced by the vaccine.
As shown in Fig. 3 a, vaccination induced SIV-specifi  c 
neutralizing antibody responses in all animals. In fact, the 
vaccine induced antibodies capable of neutralizing the rela-
tively neutralization-resistant (27, 28), primary isolate challenge. 
This level of neutralizing activity is only rarely found after 
natural infection in unvaccinated animals (unpublished data). 
Importantly, the secondary neutralizing antibody response 
against the challenge virus was evident within 7–10 d after 
challenge in all vaccinated animals.
Interestingly, after challenge, the sham-treated animals 
achieved higher titers of neutralizing antibodies against the 
T cell line–adapted (TCLA) strain of SIV compared with the 
vaccinated animals. This may be a refl  ection of the lower 
  total antigen load in the vaccinated animals, a consequence 
of the preexisting immune responses. Despite these higher 
  responses, virus was still better resolved in the vaccinated ani-
mals, highlighting the potential importance of an ability to 
Figure 1.  Viral dynamics in vaccinated macaques challenged with 
SIV. 12 animals were vaccinated with a DNA-prime rAd boost regimen. 
Six received empty vectors (left panels, open circles), and six received SIV 
gene–encoding vectors (right panels, closed circles). In all fi  gures and 
Table I, each animal is identifi  ed by the same unique color and symbol. 
(a) Plasma VL. Sham-vaccinated animals followed a typical course, reaching 
peak plasma VLs of 107 copies per ml. With one exception (animal no. 4934, 
green circles), vaccinated animals reached peak VL a few days earlier 
and at nearly 1 log lower level. The lines represent fi  ts to the geometric 
mean VLs, and the sham fi  t is reproduced in light gray on the right panel 
for comparison. (b) Cell-associated VL. The number of SIV copies per 
105 memory CD4 cells was determined by qPCR on purifi  ed, sorted total 
memory CD4 subsets from blood (top panels) or jejunal biopsies (bottom 
panels). The number of memory CD4 cells infected at any time point was 
nearly 10-fold lower in vaccinated animals, indicating that far fewer cells 
were infected and thereby destroyed.
Figure 2.  CD4 T cell dynamics in vaccinated animals challenged 
with SIV. (a) The naive/memory ratio is shown for peripheral tissues 
(jejunal samples have essentially no naive T cells) before (P) and after viral 
challenge. In sham-vaccinated animals, a substantial preferential destruc-
tion of memory T cells proceeds in all tissues. In contrast, vaccinated 
  animals show a dramatically different course of dynamics, with a rela-
tively high preservation of memory T cells. (b) CD4 memory loss was 
  computed as the change in representation within T cells compared with 
the prechallenge time point for each animal. The cross-sectional data for 
all animals measured on days 10–28 is shown for all four tissues. Statisti-
cally signifi  cant preservation of CD4 memory T cells was seen throughout 
the animals.1536  VACCINATION PRESERVES MEMORY CD4 T CELLS | Mattapallil et al.
neutralize the primary SIVmac251 challenge strain versus the 
TCLA strain for containment of viral replication once estab-
lished. Indeed, prechallenge and early secondary neutraliza-
tion responses to the challenge strain negatively associate with 
the peak VL achieved (Fig. 3 b). Of note, vaccinated animal 
number 4934, which achieved the highest peak VL, showed 
the lowest neutralizing antibody response against the chal-
lenge virus as well as the highest loss of memory CD4 T cells 
among all of the vaccinated animals.
The vaccine regimen also induced SIV-specifi  c CD4 (Fig. 
4 a) and CD8 (Fig. 4 b) T cell responses in both mucosal and 
peripheral tissues, measured 4 wk before challenge. Responses 
included expression of IFN-γ, IL-2, and TNF-α (Fig. S1). 
These responses were maintained until the day of challenge. 
After challenge, a signifi  cant expansion of SIV-specifi  c CD4 
(Fig. 4 c) and CD8 (Fig. 4 d) T cells occurred. This rapid 
  anamnestic response represented an expansion of eff  ector 
T cells preferentially producing IFN-γ (Fig. 4 e and Fig. S2, 
which is available at http://www.jem.org/cgi/content/full/
jem.20060657/DC1). The T cell response in vaccinated ani-
mals waned after day 14 as antigen load dropped. We did not 
detect any signifi  cant qualitative diff  erences between the an-
amnestic responses and the de novo responses; however, the 
de novo responses never reached the same magnitude after 
infection and peaked several days later compared with vacci-
nated animals. Notably, previous studies demonstrated that de 
novo–generated T cell responses arose only after the destruc-
tion of CD4 T cells in unvaccinated animals (3).
Previous studies have shown that systemic immunizations 
using recombinant vectors could generate mucosal immune 
responses (29–31). Consistent with this, both CD4 and CD8 
T cell responses were induced in the jejunum (Fig. S1). 
This may contribute to the protection observed at mucosa. 
The quantitatively lower levels of antigen-specifi  c T cells we 
observed in the jejunum, however, may have contributed to 
the relatively lower protection of memory CD4 T cells in 
that tissue.
Preferential infection of SIV-specifi  c cells
Douek et al. (11) demonstrated that HIV-specifi  c memory 
CD4 T cells are preferentially targeted by HIV, carrying ap-
proximately two- to fi  vefold more virus than total memory 
cells. This raised the concern that vaccine-induced virus-
  specifi  c T cells may serve to accelerate infection. Indeed, 
a vaccine that induced solely CD4 T cell responses seemed 
to augment disease course (12). To address this issue in our 
study, we sorted SIV-specifi  c CD4+ IFN-γ+ or TNF-α+ 
cells, or total CD4 memory T cells, and quantifi  ed the infec-
tion rate using a quantitative PCR (qPCR) assay for SIV-gag. 
This assay was performed after challenge on vaccinated ani-
mals to quantify the infection of vaccine-induced CD4 T cells 
and on sham controls to quantify the infection of de novo–
generated CD4 T cells.
Our analysis confi  rmed that vaccine-induced SIV-specifi  c 
CD4 T cells may serve as preferential targets for viral infec-
tion (Fig. 4 f). We observed a trend toward a twofold greater 
cell-associated VL in SIV-specifi   c CD4 T cells compared 
with total CD4 memory. In sham-vaccinated animals, the 
same rate of preferential infection was found for de novo–
generated CD4 T cells as observed for the vaccine-induced 
CD4 T cells at later time points. However, at the earliest time 
point (day 7) there was a signifi  cantly lower rate of infection 
in the de novo–generated SIV-specifi  c CD4 T cells. We hy-
pothesize that the SIV-specifi  c CD4 T cells from this time 
point are highly proliferating cells just arising from the naive 
CD4 pool. Because naive T cells are resistant to viral infec-
tion, these cells are just acquiring susceptibility. By day 10, 
SIV-specifi  c CD4 T cells in sham-treated animals were as 
preferentially infected as those from vaccinated animals.
Extent of CD4 memory T cell loss predicts rate 
of progression
Memory CD4 T cells play a central, initiating role in gener-
ating secondary immune responses against previously en-
countered pathogens by providing help to both B and CD8 
T cells. Therefore, we had hypothesized that the degree of 
Figure 3.  Humoral responses in vaccinated animals challenged with 
SIV. The plasma levels of neutralizing antibodies were quantifi  ed at 
  various times before, during, and after the immunization and SIV challenge. 
(a) Shown are the neutralizing titres to the primary SIVMac251 isolate 
(top) or to the more-easily neutralized laboratory-adapted strain (bottom). 
P, preimmunization titres. (b) The peak plasma VL is shown against 
the neutralization titre against primary SIVMac251 measured at day 0 
(prechallenge) or day 7 after challenge (signifi  cance was determined by 
two-sided paired t tests). The two animals that were killed at day 7 and 
did not reach peak VL are excluded. Note that although prechallenge neu-
tralizing titres for animals 4942 (brown) and 4844 (blue) were low, they 
were boosted at day 7, indicating that they were present but undetectable 
at time of challenge.JEM VOL. 203, June 12, 2006  1537
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destruction of this compartment during acute SIV/HIV in-
fection may predict the rapidity of onset of immunodefi  -
ciency and AIDS during the chronic stage of disease (1). 
A corollary of this hypothesis is that vaccination before chal-
lenge, by preserving memory CD4 T cells, would lead to 
a better disease outcome.
We quantifi  ed the dynamics and cell-associated VLs of 
peripheral blood memory CD4 T cells during the fi  rst 4 wk 
of infection for animals in a larger vaccine study. Details of 
this study are reported elsewhere (32). In brief, 30 animals 
were vaccinated with six diff  erent regimens (including a sham 
vaccination) that incorporated diff   erent combinations of 
DNA priming and rAd boosting. These animals have been 
followed for more than 3 yr after intravenous SIVmac251 
challenge. We measured the CD4 memory T cell numbers 
and associated VLs at days 7, 14, and 28 after challenge using 
cyropreserved specimens.
We correlated the degree of memory T cell loss (mea-
sured phenotypically) against survival. As shown in Fig. 5 a, 
animals that lived longer had signifi   cantly greater preser-
vation of CD4 memory T cells during the acute phase. By 
grouping the animals into terciles based on the extent of 
CD4 memory destruction during the acute phase, signifi  -
cantly diff  erent survival curves are observed (Fig. 5 b). This 
predictive power is not seen for peak VL (Fig. 5 c) nor for 
total CD4 T cell loss (Fig. 5 d). Furthermore, the signifi  -
cance was seen whether the analysis was performed on all 
animals or only the subset receiving immunogenic vaccines. 
A proportional hazards analysis of the three continuous vari-
ables (CD4 memory T cell destruction, peak VL, and/or 
  total CD4 T cell destruction) revealed that only the memory 
T cell destruction had statistically signifi  cant power to pre-
dict survival (combined model, P = 0.02, risk ratio = 1.06 
[range, 1.01–1.12] per memory CD4 T cell destroyed per μl 
of blood). These data show that the extent of memory CD4 
T cell destruction during the acute phase of disease is a po-
tentially critical surrogate marker for predicting subsequent 
disease progression.
Figure 4.  SIV-specifi  c T cell responses in vaccinated animals 
challenged with SIV. T cells isolated from various tissues before SIV 
challenge were stimulated with overlapping peptide pools from the SIV 
gag and envelope proteins. The fraction of CD4 (a) or CD8 (b) T cells 
making IFN-γ, TNF-α, and/or IL-2 is shown after the full immunization 
regimen, 1 mo before SIV infection. After challenge, SIV-specifi  c CD4 (c) 
and CD8 (d) T cells expand in all animals in peripheral blood (and other 
tissues; not depicted). The expansion was greater and peaked earlier for 
the vaccinated animals. (e) The quality of the T cell response is shown 
during the challenge phase for vaccinated animals. The prechallenge 
responses were typical of memory T cells (dominated by IL-2 and TNF). 
After challenge, dramatic expansion of effector T cells producing IFN-γ 
was observed (see Fig. 2 for the detailed analysis of the quality of the 
responses for all animals). (f) SIV-specifi  c CD4 memory T cells and total 
CD4 memory T cells were sorted from PBMC specimens at different time 
points from animals with suffi  cient SIV-specifi  c responses to isolate at 
least several hundred cells. SIV gag DNA was quantifi  ed by qPCR. For 
each specimen, the ratio of the gag DNA signals in SIV-specifi  c CD4 T cells 
to total memory CD4 T cells is shown. Values >1 indicate preferential 
infection of SIV-specifi  c CD4 T cells, and values <1 indicate resistance 
to infection. Shown are the p-values for tests that the distributions 
have a mean different than 1.1538  VACCINATION PRESERVES MEMORY CD4 T CELLS | Mattapallil et al.
DISCUSSION
HIV infection causes a biphasic destruction of CD4 T cells. 
A massive loss of memory CD4 T cells mediated by direct 
viral infection occurs during the early acute stages, followed 
by slow, progressive loss of CD4 T cells mediated by 
  numerous mechanisms during the chronic stage (33, 34). 
After this initial destruction during the acute phase is likely 
a homeostatically driven expansion of remaining memory 
CD4 T cells—an expansion that cannot replace antigen-
specifi  c responses lost during the acute phase. Given the 
critical role of preexisting memory CD4 T cells in generat-
ing secondary immune responses, the loss of these antigen-
specifi  c responses during acute infection sets the stage of 
onset of immunodefi  ciency. Our studies show that animals 
sustaining lower peak plasma VLs also exhibit lower levels 
of memory CD4 T cell loss. Thus, clinical observations that 
high peak plasma VLs are associated with more rapid pro-
gression in HIV-infected humans can be explained by the 
concomitant greater destruction of the CD4 memory com-
partment during the acute stage. In addition, our fi  ndings 
underscore the necessity for HIV vaccines to ameliorate the 
virus-mediated destruction occurring in the fi  rst 2–4 wk 
after infection.
We evaluated the ability of a systemic DNA-prime rAd 
boost vaccine regimen to induce adaptive immune responses 
that could alter disease progression. DNA priming was per-
formed three times at 1-mo intervals, with the rAd boost 
3 mo later. Challenge with SIV Mac251 was initiated 2 mo af-
ter the rAd immunization. As has been observed for this regi-
men in the SHIV challenge model (13, 16), vaccination was 
  partially protective in that the viral dynamics were tempered, 
with peak plasma VLs in most animals being  10-fold lower 
than sham-treated controls after SIV challenge. Although this 
reduction (from 107 to 106 viral copies/ml of blood) may 
seem inconsequential, it was in fact accompanied by a strong 
reduction in the number of CD4 memory T cells that were 
infected and destroyed. Indeed, vaccination has a dramatic 
impact on this compartment. Whereas sham-treated animals 
lost 50–80% of their memory CD4 T cells, vaccinated ani-
mals lost only 5–20%, indicating that a large majority of pre-
existing CD4 memory responses were preserved by the 
vaccine regimen. Early preservation of these memory CD4 
T cells has a signifi  cant impact on the outcome of disease 
course. Loss of fewer memory CD4 T cells was directly associated 
with better long-term survival.
Importantly, the systemic vaccination elicited mucosal 
T cell responses and, after challenge, provided protection against 
the catastrophic loss of CD4 T cells in the gut. The impor-
tance of this site to the pathogenesis of SIV/HIV has become 
clear in the last few years (1, 2, 4, 15, 35–38). By far, the mu-
cosa accounts for the greatest loss of CD4 T cells from the 
body. Thus, by preserving even 25% of the cells at this site, 
vaccination should dramatically improve mucosal immunity 
and health of the infected host.
Several factors could have played a role in the lower level 
of preservation observed in mucosal tissues, including the 
high dose of highly pathogenic SIVmac251, intravenous 
route of infection, and the disorganized nature of the eff  ec-
tor mucosal compartment sampled in this study. Unlike the 
peripheral tissues, CD4 T cell targets are loosely distributed 
in the jejunal mucosa and could serve as readily available tar-
gets for the rapidly disseminating virus after intravenous 
challenge. These cells, once infected, are rapidly destroyed 
either by preexisting immune responses or virally mediated 
lysis. It is possible that a low dose of challenge by the mucosal 
route may lead to higher levels of memory CD4 T cell 
  preservation in the mucosal tissues, as shown recently by 
Miller et al. (39). Additionally, it is possible that mucosal 
  immunization may generate better and stronger mucosal 
  immune responses that could more eff  ectively prevent the 
loss of mucosal CD4 T cells. Nonetheless, it is important to 
appreciate that even a 25% preservation of memory cells, 
compared with the near-total destruction in unvaccinated 
animals, could have signifi  cant long-term benefi  ts for main-
taining the integrity of the mucosal immune system, as has 
been demonstrated by Picker et al. (40) These studies showed 
that animals that failed to repopulate mucosal tissues pro-
gressed faster compared with animals that partially repopu-
lated the mucosal tissues.
Figure 5.  CD4 memory T cell destruction during acute SIV chal-
lenge predicts survival. 30 macaques (24 receiving different vaccine 
regimens and 6 receiving sham vaccines) were challenged with SIV Mac251 
and followed for more than 2 yr. (a) The preservation of CD4 T cells after 
acute challenge (i.e., fraction of CD4 memory cells remaining at day 14 
compared with day 7) is shown for animals that survived less than 1 yr, 
1–2 yr, or more than 2 yr. (b) Kaplan-Meier survival curves for animals 
grouped into terciles based on the extent of CD4 memory T cell destruc-
tion during the acute phase. Animals with the best preservation of CD4 
memory (green) survived much longer than those with greater destruction. 
The analysis was still highly signifi  cant when excluding the sham-
  vaccinated animals (inset). There was no signifi  cant power of the peak VL 
(c) or the loss of total CD4 T cells (d) to predict survival for either the total 
group or for only vaccinated animals.JEM VOL. 203, June 12, 2006  1539
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Preservation of mucosal CD4 T cells has important impli-
cations for disease outcome and the onset of immunodefi  -
ciency. Mucosal tissues harbor most of the T cells in the body 
and are home to numerous pathogens. Loss of preexisting 
memory CD4 T cells severely compromises the ability of the 
mucosal immune system to maintain protective responses 
leading to the onset of numerous secondary infections. In 
  addition, rapid infection and destruction of emerging HIV-
  specifi  c CD4 T cell responses may severely compromise the 
generation and maintenance of subsequent HIV-specifi  c 
CD8 T cell responses, leading to a failure to control viral in-
fection. By maintaining the integrity of the mucosal immune 
system, vaccination can blunt the devastating eff  ects of HIV 
and ensure better long-term outcome.
The vaccine induced both humoral and cellular immune 
responses. Although both have been implicated in the con-
trol of virus after challenge, the relatively small size of our 
study did not reveal a clear correlate of protection for either 
of these arms of the immune response. Nonetheless, our data 
suggest that the neutralization titres against the primary chal-
lenge isolate may associate with the control of peak plasma 
VL (and peak cell-associated VL). Notably, animal number 
4934 had essentially undetectable neutralizing titres against 
primary SIVmac251 before challenge that did not boost 
by day 7 and sustained the highest VL amongst vaccinated 
  animals—in the same range as the sham-treated animals. This 
animal had good neutralizing titres against the TCLA virus 
as well as systemic CD4- and CD8-specifi  c responses. The 
T cell responses may have contributed to the eventual better 
control of viremia in this animal compared with sham-treated 
animals. These results are in concert with studies showing 
that administration of neutralizing antibodies attenuates 
pathogenicity in the SIV or SHIV models (6, 9, 41). Further-
more, our results complement recent studies (42) using CD8 
depletion in SIVmac239∆3-vaccinated macaques, suggesting 
that both neutralizing antibodies and CD8 T cells contribute 
to the containment of plasma viremia.
The generation of SIV/HIV-specifi  c CD4 responses by a 
vaccine posed a conundrum; namely, although these responses 
are associated with better viral control by CD8 T cells, the 
cells provide a readily available substrate for viral replication. 
We found a similar level of preferential infection of SIV-
  specifi  c CD4 cells in both vaccinated and unvaccinated animals 
as Douek et al. (11) found for chronically HIV-infected 
  humans. Using a vaccine that induced principally CD4 
  responses, Staprans et al. (12) found that challenge led to 
  exacerbated disease. In contrast, our vaccine regimen, which 
induces broad CD4, CD8, and humoral responses, resulted in 
a signifi  cantly tempered pathogenesis. Thus, we conclude that 
the trend toward preferential infection of vaccine-induced 
CD4 T cells does not bode poorly for infected subjects.
In summary, we demonstrate that cell-associated VLs 
and evaluation of memory CD4 T cell dynamics in multiple 
tissues serve as powerful correlates for measuring vaccine-
induced protection. We show that a DNA-prime rAd boost 
vaccination dramatically reduces the level of infection and 
destruction of preexisting memory CD4 T cells during 
the early explosive phase of acute infection. Preservation of 
these cells will signifi   cantly aid in warding off    immuno-
defi   ciency and the establishment of secondary infections. 
  Finally, preservation of memory CD4 T cells was associated 
with better long-term outcome and survival. Thus, in the 
absence of sterilizing immunity, eff  ective vaccination signif-
icantly blunts the destructive eff  ects of early infection and 
plays an important role in maintaining the integrity of the 
immune system.
MATERIALS AND METHODS
Animals, infection, and samples. 42 colony-bred healthy rhesus ma-
caques (Macaca mulatta) housed at Bioqual Inc. were used in this study. 
  Animals were housed in accordance with American Association for Accredi-
tation of Laboratory Animal Care guidelines and were seronegative for SIV, 
SRV, and STLV-1. Animals were infected with 100 animal infectious doses 
of uncloned pathogenic SIVmac251 intravenously. All animal studies were 
approved by the Vaccine Research Center (NIH) Institutional Animal Care 
and Use Committee.
Vaccination. Animals were grouped into vaccine (n = 6) and sham groups 
(n = 6). Animals in the vaccine group received 4.5 mg of DNA encoding 
SIVmac239 envelope and 4.5 mg of DNA encoding an SIVmac239 gag-pol 
fusion protein at 0, 4, and 8 wk (13, 16). DNA was administered into the 
quadriceps muscles using a gene gun. These animals were boosted with 1011 
particles of rAd-5 encoding SIVmac239 envelope and 1011 particles of rAd-5 
encoding SIVmac239 gag-pol administered intramuscularly at 24 wk. Sham 
controls received empty DNA vectors (0, 4, and 8 wk) and empty rAd5 
  vectors (20 wk). For Fig. 5, data were aggregated from 30 animals followed 
for more than 2 yr after challenge. Animals were vaccinated using a similar 
schedule as described above. There were fi  ve groups of six animals each: 
sham; rAd5 encoding SIVmac239 gag-pol fusion protein (no DNA prime); 
DNA encoding SIVmac239 envelope followed by rAd5 encoding envelope; 
DNA encoding SIVmac239 gag-pol followed by rAd5 encoding gag-pol; 
and DNA encoding SIVmac239 gag-pol and DNA encoding envelope fol-
lowed by rAd5 encoding gag-pol and rAd5 encoding envelope. DNA was 
manufactured by Althea.
Tissue sampling. PBMCs were isolated by density gradient centrifugation. 
Cells were isolated from jejunum and LN biopsy and necropsy samples 
as  described previously (15). Plasma viral RNA levels were determined 
by real-time PCR (ABI Prism 7700 sequence detection system; Applied 
Biosystems) using reverse-transcribed viral RNA as templates as described 
previously (432).
Antibodies and fl  ow cytometry. All antibodies were purchased from BD 
Biosciences, either conjugated or unconjugated, and derivatized in our labo-
ratory. All reagents were validated and titrated using rhesus macaque PBMCs. 
For phenotypic analysis, freshly isolated cells were labeled simultaneously 
with the following combinations of antibodies: CD3-Cy7APC, CD8-
Cy5.5-PE, CD4-cascade blue, CD45RA-TRPE, CD95-APC, CCR5-PE, 
and CD11a-Cy7PE. SIV-envelope– and SIV-gag–specifi  c responses were 
determined using overlapping peptides as described previously (3, 44, 45). 
Control cultures were set up for each sample without SIV peptides. After 
stimulation, cells were labeled with cell surface markers (CD3, CD4, CD8, 
CD45RA, and CD95) and ethidium monoazide (to discriminate live from 
dead cells [46]). After fi  xing (Fix/Perm kit; BD Biosciences), cells were per-
meabilized and labeled with IL-2-PE, IFN-γ-FITC, and TNF-α-Cy7PE 
(BD Biosciences). Labeled cells were fi  xed with 0.5% paraformaldehyde and 
analyzed using an LSR II or a modifi  ed Becton Dickinson DiVa.
Cell-associated VLs in sorted subsets of naive and memory CD4 T cells 
(discriminated on basis of CD45RA and CD95 expression [47]) were 
  determined using a qPCR. Preferential infection of SIV-envelope– and 1540  VACCINATION PRESERVES MEMORY CD4 T CELLS | Mattapallil et al.
SIV-gag–specifi  c CD4 T cells was determined by measuring SIV-gag DNA 
in total IFN-γ+ and/or TNF-α+ cells sorted from peripheral blood samples 
after stimulation with overlapping peptide pools.
qPCR assay for SIV-gag DNA. T cell–associated viral DNA was mea-
sured by a qPCR assay for SIV gag using a PerkinElmer ABI 7700 instrument 
using SIV gag primers and probe as described previously (11, 23).
SIV neutralization assays. Neutralizing titres were determined in a lucif-
erase reporter gene assay performed in 5.25.EGFP.Luc.M7 cells as described 
previously (47). Neutralizing antibody titres are the serum dilution at which 
relative luminescence units were reduced by 50% compared with virus infec-
tion in the absence of test serum. The primary stock of SIVmac251 was pre-
pared in human PBMCs. The TCLA stock of this virus was prepared in H9 
cells. All serum samples were heat inactivated at 56°C for 1 h before assay. All 
assays were performed blinded to the identity of the animal or time points.
Data analysis. Flow cytometric data was analyzed using FlowJo version 6.1 
(Tree Star, Inc). Statistical analyses and graphical presentations were com-
puted with JMP version 5.1.2 (SAS Institute) using nonparametric Wilcoxon 
rank tests for distributions or Wilcoxon Chi-square for the Kaplan-Meier 
survival analysis.
Online supplemental material. Fig. S1 illustrates the data analysis strat-
egy used to identify memory CD4 and CD8 T cells using the multicolor 
immunophenotyping panel. In addition, this fi  gure shows examples of 
  cytokine (TNF-α, IFN-γ, and IL-2) expression patterns for stimulated 
and control cell samples from jejunum, inguinal LNs, mesenteric LNs, and 
PBMCs from a single animal. Fig. S2 shows the individual data points for 
all animals at various time points after challenge to show the representa-
tion of each possible combination of the three cytokines for SIV-specifi  c 
CD4 and CD8 T cells. These data values were averaged to generate the pie 
charts shown in Fig. 4. Figs. S1 and S2 are available at http://www.jem.
org/cgi/content/full/jem.20060657/DC1.
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